Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer
Summary: BRD4 plays a major role in the transcription networks orchestrated by androgen receptor (AR) in castration-resistant prostate cancer (CRPC). Several BET inhibitors (BETi) that displace BRD4 from chromatin are being evaluated in clinical trials for CRPC. Here, we describe mechanisms of acqui...
Main Authors: | Aishwarya Pawar, Paradesi Naidu Gollavilli, Shaomeng Wang, Irfan A. Asangani |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-02-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124718301797 |
Similar Items
-
The role of BET proteins in castration-resistant prostate cancer dissemination
by: Shafran, Jordan Seth
Published: (2020) -
New Therapeutics to Treat Castrate-Resistant Prostate Cancer
by: Ömer Acar, et al.
Published: (2013-01-01) -
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
by: Brandon Bumbaca, et al.
Published: (2018-07-01) -
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01) -
Castration-resistant prostate cancer: latest evidence and therapeutic implications
by: Daniel L. Suzman, et al.
Published: (2014-07-01)